Autophagy and Senescence in Antiestrogen Resistance
Plain-language guide to the 2024 review on how autophagy and reversible senescence may help ER-positive breast cancer survive endocrine therapy and CDK4/6 pressure
This section breaks one important 2024 review into smaller, easier pages.
The central idea is simple.
Many ER-positive breast-cancer cells do not die straight away under treatment pressure.
Some switch into autophagy.
Some enter senescence.
Both states may help cells stay alive long enough to build durable resistance.
Review we are unpacking
McGrath MK, Abolhassani A, Guy L, Elshazly AM, Barrett JT, Mivechi NF, Gewirtz DA, and Schoenlein PV (2024).
Autophagy and senescence facilitate the development of antiestrogen resistance in ER-positive breast cancer.
Frontiers in Endocrinology. 15:1298423.
What this review argues
Endocrine therapies and CDK4/6 inhibitors often trigger protective survival states.
Those survival states may buy time for later resistance mutations and rewiring.
A future strategy may be to add an autophagy blocker and later a senolytic, at the right point in the sequence.
This is a review-based framework.
It is not a proven routine treatment pathway.
Hydroxychloroquine, senolytics, and treatment sequencing ideas remain investigational in this setting.
Read this section in order
Also useful alongside this section
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.